NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

At some point last year, someone posted a page from the Cancer Research Institute, which I will include below. It could be inaccurate, no doubt. It is also possible it is only approved as an adjuvant for another therapy and sometimes, because a drug is not approved as a standalone drug, it is not widely known. Poly-ICLC in my view, has no chance of ever being a standalone drug. All it does is trick the immune system into believing that there are indications of a viral infection, though that is literally NOT the case, and it causes the immune system to rev up. The reality is, for immune therapies, this is a very useful tactic to add to a treatment like DCVax-L because it revs up all kinds of immune processes that further assist the immune system's response, for instance, to cancer and the various antigens that have viral origins in many cancers, but particularly GBM.

But I am completely willing to concede that I have no idea. I said it was approved because every time I said it wasn't, previously, someone corrected me. So I presumed that was correct information. It may be wrong, or we all might simply not have the full information.

As I said, this could be wrong, or we could be not fully cognizant of all of the details. But I do note that adjuvants for vaccines do not require immense effort to be approved generally, so long as they have been shown to be safe and that they have an effect of making a vaccine more powerful. Adjuvants come in a variety of types.

https://www.cancerresearch.org/treatment-types/immunomodulators

Adjuvants
Imiquimod: an immune adjuvant targeting the Toll-like receptor 7 (TLR7) pathway; approved for subsets of patients with basal cell carcinoma

Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma